Ravi Vij MD MBA

Clinical Trials

• Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission Start of enrollment: 2004 Jan 01

  Completed

  Phase 2

• PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma Start of enrollment: 2005 Sep 01

  Terminated

  Phase 2

• Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant Start of enrollment: 2004 Jun 01

  Terminated

  Phase 3

• A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2005 Mar 01

  Terminated

  Phase 2

• A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes Start of enrollment: 2006 Aug 01

  Completed

  Phase 2

• A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma Start of enrollment: 2007 Jan 01

  Completed

  Phase 2

• Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Start of enrollment: 2007 Mar 01

  Completed

  Phase 2

• A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma Start of enrollment: 2006 Oct 01

  Completed

  Phase 1

• Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities Start of enrollment: 2007 Feb 01

  Completed

  Phase 2

• Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation Start of enrollment: 2007 Nov 01

  Terminated

  Phase 2

• Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia Start of enrollment: 2008 May 01

  Completed

  Phase 1

• LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) Start of enrollment: 2008 Jun 01

  Completed

  Phase 1, Phase 2

• Oral Clofarabine for Acute Myeloid Leukemia Start of enrollment: 2009 Jan 01

  Completed

  Phase 1

• Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma Start of enrollment: 2008 Nov 01

  Completed

  Phase 1, Phase 2

• A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma Start of enrollment: 2008 Aug 01

  Completed

  Phase 2

• CC-4047 (Pomalidomide) for Graft vs. Host Disease Start of enrollment: 2009 Feb 01

  Completed

  Phase 2

• Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease Start of enrollment: 2010 Oct 01

  Completed

  Phase 1

• Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2009 May 05

  ACTIVE_NOT_RECRUITING

  PHASE2

• Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia Start of enrollment: 2011 Feb 01

  Completed

  Phase 1, Phase 2

• Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant Start of enrollment: 2009 Dec 01

  Completed

  Phase 1

• Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML) Start of enrollment: 2010 May 01

  Completed

  Phase 1

• Azacitidine and Lenalidomide for Acute Myeloid Leukemia Start of enrollment: 2010 Apr 01

  Completed

  Phase 1, Phase 2

• Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy Start of enrollment: 2010 Jan 01

  Terminated

  Phase 1, Phase 2

• Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant Start of enrollment: 2010 Apr 29

  Completed

  Phase 1

• Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2010 Feb 01

  Completed

  Phase 2

• IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML) Start of enrollment: 2010 May 01

  Terminated

  Phase 1

• Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma Start of enrollment: 2009 Sep 01

  Completed

  Phase 1, Phase 2

• Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2010 Feb 01

  Completed

  Phase 1, Phase 2

• Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) Start of enrollment: 2010 Sep 02

  Completed

  Phase 1

• Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant Start of enrollment: 2010 Dec 01

  Terminated

  Phase 2

• Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia Start of enrollment: 2010 Oct 01

  Completed

  Phase 1

• Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors Start of enrollment: 2011 Apr 01

  Completed

  Phase 2

• Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML Start of enrollment: 2010 Nov 01

  Completed

  Phase 1

• Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia Start of enrollment: 2010 Jul 15

  Completed

  Phase 2

• Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2012 May 14

  Completed

  Phase 1, Phase 2

• Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents Start of enrollment: 2011 Jun 01

  Completed

  Phase 2

• Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia Start of enrollment: 2011 Jul 01

  Completed

  Early Phase 1

• Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Start of enrollment: 2011 Jul 01

  Completed

• Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma Start of enrollment: 2012 Jun 01

  Terminated

  Early Phase 1

• Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation Start of enrollment: 2012 Sep 01

  Terminated

  Phase 2

• Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation Start of enrollment: 2013 Feb 25

  Completed

  Phase 1

• Geriatric Assessments in Senior Adults With Multiple Myeloma Start of enrollment: 2012 Sep 01

  Completed

• Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation Start of enrollment: 2013 Apr 15

  Terminated

  Phase 1, Phase 2

• Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Aug 11

  Terminated

  Phase 1, Phase 2

• Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma Start of enrollment: 2014 Mar 19

  Completed

  Phase 2

• Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Feb 28

  Terminated

  Phase 1

• Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Start of enrollment: 2014 Aug 20

  Completed

  Phase 2

• A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation Start of enrollment: 2015 Jan 20

  Terminated

  Phase 2

• Falls Risk Questionnaire in Older Adults With Cancer Start of enrollment: 2014 Aug 01

  Completed

• Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma Start of enrollment: 2015 Feb 20

  Completed

  Phase 1

• A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies Start of enrollment: 2014 Aug 25

  Terminated

  Phase 1

• Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma Start of enrollment: 2015 Jan 20

  ACTIVE_NOT_RECRUITING

  PHASE2

• Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement Start of enrollment: 2016 Sep 01

  Active, not recruiting

  Phase 2

• Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma Start of enrollment: 2017 Nov 22

  ACTIVE_NOT_RECRUITING

  PHASE2

• Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma Start of enrollment: 2020 Apr 03

  Terminated

  Phase 1

• Join now to see all